~~CURACRENT~~ CURRENT REPORT FOR ISSUERS SUBJECT TO THE

1934 ACT REPORTING REQUIREMENTS

FORM 8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act

~~September 30~~October 16, 2015

Date of Report

(Date of Earliest Event Reported)

Tianyin Pharmaceutical Co, Inc.

(Exact name of registrant as specified in its charter)

Delaware

000-52236

20-4857782

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 ~~South Renmin Road Chengdu, P. R. China, 610041~~

South Renmin Road

Chengdu, P. R. China, 610041

(Address of principal executive offices (zip code))

+011-86-28- 8551-6696

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a - 12)

☐o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))

Section 8 3 – ~~Other~~Securities ~~Events~~and Trading Markets

Item 8 3.01. ~~Other~~Notice ~~Events~~of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

~~In late~~On ~~September~~October of16, 2015, Tianyin Pharmaceutical Co., Inc. (the “Company”) ~~was~~received ~~informed~~a ~~that~~notice anfrom ~~investigation~~the ~~had~~NYSE ~~been initiated~~MKT ~~against~~Staff ~~Dr.~~indicating ~~Guoqing~~that ~~Jiang,~~the ~~Chief~~Company ~~Executive~~is ~~Officer,~~below ~~Acting~~certain ~~Chief Financial Officer and Chairman~~ of the ~~Company~~continued bylisting ~~Public Order~~standards ~~Corps~~ of ~~Sichuan~~the ~~Province~~NYSE ~~Public~~MKT ~~Security Department~~ (the “~~SPPSD~~Exchange”) inas ~~connection~~set ~~with~~forth ~~the~~in ~~temporary~~Sections ~~halt~~134 ~~of production~~ and ~~sale~~1101 of the NYSE MKT Company’s ~~Hugan Tablets in mid 2014~~Guide, ~~which~~due ~~was~~to ~~disclosed~~the delay in afiling ~~Current~~its Annual Report on Form 810-K ~~filed by~~for the ~~Company~~year onended ~~April~~June 730, ~~2014,~~2015 ~~amended~~(the ~~subsequently~~“Form 10-K”) onbeyond ~~May~~the ~~14,~~extended ~~2014,~~filing ~~May~~due ~~23,~~date. ~~2014~~Currently ~~and~~the ~~July~~Company 8,is ~~2014,~~working asdiligently ~~well~~to ascompile ~~our~~and ~~periodic reports~~disseminate ~~thereafter.~~the Asinformation required ato ~~part~~be ofincluded in the ~~investigation,~~Form ~~certain~~10-K. ~~files~~The ~~of the~~ Company ~~have~~expects ~~been~~to ~~taken~~file by the ~~SPPSD,~~Form ~~which~~10-K ~~has~~before ~~caused additional delay in~~ the ~~Company’s~~deadline ~~annual~~set ~~audit~~by ~~for~~ the ~~fiscal year ended June 30, 2015~~Exchange.

~~The~~On ~~Company’s~~October ~~Board~~19, of2015, ~~Directors~~we isissued ~~currently~~a ~~looking~~press release ~~into~~regarding ~~this~~the ~~matter and~~receipt ~~ascertaining~~of the ~~nature~~notice ~~and~~of ~~scope~~delinquency offrom the ~~investigation~~NYSE MKT. ~~The~~A ~~Company~~copy ~~will~~of ~~file~~the anpress ~~amendment~~release tois ~~provide~~attached ~~more~~hereto ~~information once~~as itExhibit ~~becomes~~99.1 ~~available~~and incorporated herein in its entirety.

Section 9 – Financial Statements and Exhibits

Item 9.01: Financial Statements and Exhibits

Exhibit No.		Description

99.1		Press Release dated October 19, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TIANYIN PHARMACEUTICAL CO., INC.
	By:	/s/Guoqing Jiang
		Name: Guoqing Jiang
		Title: Chief Executive Officer
Dated: October 16, 2015

	TIANYIN PHARMACEUTICAL CO., INC.

	By:	/s/ Guoqing Jiang
		Name: Guoqing Jiang Title: Chief Executive Officer, Chairman

Dated: October 19, 2015

Filing Compare · TIANYIN PHARMACEUTICAL CO., INC.